Radiation therapy for BCG-resistant bladder CIS
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a type of bladder cancer called high-risk non-muscle-invasive bladder cancer, mostly made of transitional cells (the most common bladder cell type).
- Your cancer did not respond to BCG treatment (it came back or got worse), and you either cannot have or have chosen not to have your bladder removed.
- You have carcinoma in situ (a flat, high-grade spot on the bladder lining), with or without other high-grade tumors (Ta or T1).
- You are in fairly good health (able to do daily activities with little help) and have normal organ function.
- You have not had radiation to the pelvic area in the last 5 years, and you are not currently on chemotherapy for bladder cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a new online adaptive radiotherapy technique for bladder cancer that adjusts the radiation plan daily based on changes in the bladder. It aims to improve treatment accuracy and reduce side effects.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.